Galcanezumab, a monoclonal antibody against calcitonin gene-related peptide, may significantly improve daily functioning, disability, and health-related quality of life in a rapid and sustained fashion in patients with migraine.
Botulinum toxin was found to reduce migraine frequency in adults with chronic migraine by two days per month without significant adverse events.
Less pronounced clinical and radiologic features in asymptomatic idiopathic intracranial hypertension (IIH) may serve as early indicators for symptomatic IIH in children.
The use of a smartphone-based progressive muscle relaxation was found to be associated with a reduction in monthly headache days and depression scores in patients with migraine.
Galcanezumab was found to be beneficial in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.
Lasmiditan may provide effective acute relief from migraine, with sustained improvements in freedom from pain, most bothersome symptoms, total migraine, and disability.
Individuals with migraine who are categorized as “pro-nociceptive” may exhibit a greater response to prophylactic treatments with serotonin norepinephrine reuptake inhibitors.
In patients with headaches, imaging may show widespread higher white matter diffusion compared with in headache-free individuals in the general population.
Idiopathic intracranial hypertension may double the risk for cardiovascular disease in women.
In addition to being manufactured outside of the controls required by current Good Manufacturing Practices, these products are also being marketed for diseases without FDA approval.